JMP Securities analyst Jonathan Wolleben lowered the firm’s price target on Aura Biosciences to $25 from $30 and keeps an Outperform rating on the shares. Aura Biosciences is on track to begin dosing in its Phase 3 of AU-011 for primary choroidal melanoma in 1H23 with follow-on indications moving forward throughout the year, the analyst tells investors in a research note. Aura is also making progress in other indications with the first-in-human Phase 1 of AU-011 in bladder cancer on track for data in 2H23 and a Phase 1 for choroidal metastasis potentially starting around year-end, the firm adds.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AURA: